- Home
- BNTC
as 04-18-2025 1:32pm EST
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
| Founded: | 1995 | Country: | United States |
| Employees: | 16 | City: | HAYWARD |
| Market Cap: | 322.6M | IPO Year: | N/A |
| Target Price: | $24.71 | AVG Volume (30 days): | 64.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.08 - $16.90 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Benitec Biopharma Inc. (BNTC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director10% Owner | Mar 31 '25 | Buy | $12.93 | 16,497 | $211,736.04 | 8,802,748 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director10% Owner | Mar 26 '25 | Buy | $13.00 | 900,000 | $11,700,000.00 | 8,802,748 |
Latest Benitec Biopharma Inc. News
BNTC Breaking Stock News: Dive into BNTC Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
MT Newswires
25 days ago
Benitec Biopharma Prices $30 Million Equity Offerings
GlobeNewswire
25 days ago
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
GlobeNewswire
a month ago
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Zacks
a month ago
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
Simply Wall St.
a month ago
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans
GlobeNewswire
2 months ago
Benitec Biopharma to Participate in Upcoming Conferences in March
Zacks
2 months ago
Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
Compare BNTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BNTC Benitec Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.